Pharma stocks and the biotech sector can offer explosive gains. It also offers incredibly crushing defeats in which share prices decline precipitously....
As the psychedelic space expands rapidly and exponentially, there is a dire need for infrastructure to support the needs of the industry. Psychedelics...
A new study published in the New England Journal of Medicine found that Spravato’s esketamine was more effective than a commonly prescribed drug in treating...
California Governor Gavin Newsom has signed a bill that allows doctors to legally prescribe psychedelics when re-scheduled by the federal government. The...
5-MEO-DMT developer GH Research has provided an update on its main clinical programs. The company is notoriously short on communications outside of the...
–Topline efficacy data expected in Q4 2023 – – Preparations are underway to scale the CYB003 program to a potential Phase 3 study in early 2024...
Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed. The post News...
Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE:7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development...
Psychedelic stocks are on the rise. Despite the stigma surrounding psychedelics for personal use, controlled medical experiments indicate their usefulness...
The FDA has accepted the company’s Abbreviated New Drug Application for KETARX™ (racemic ketamine). The goal date for this priority original ANDA of...